{"entity":{"id":"rejuv-access-what-it-costs-us","kind":"technology","name":"What recovery costs in the United States","aka":[],"tldr":"More than half of United States survivors in a comparative survey reported financial difficulty, against a third in the UK. What a person pays for rehabilitation, psychological care, fertility preservation and a wig depends on their insurance, their state and their employer rather than on their cancer.","summary":"The United States is the one system on this front where the cost of recovery care is itself a clinical variable, because it determines who receives it.\n\nThe measured burden. In a cross-sectional survey of 600 cancer patients and survivors using the COmprehensive Score for financial Toxicity, with severity defined as none at 26 or above, mild at 14 to 25 and moderate or severe at 0 to 13, 55 per cent of United States participants faced financial toxicity against 34 per cent in the UK, crude odds ratio 2.44 (95% CI 1.73 to 3.42). Within the United States sample, being 65 or over, being retired and having higher household income each reduced the risk, and being female increased it, adjusted odds ratio 1.83 (95% CI 1.01 to 3.32). Age 65 reducing risk is the Medicare threshold showing up in the data.\n\nWhat determines what a person pays, in rough order of how much it matters. Whether they are insured and by whom; whether their plan covers rehabilitation therapies and for how many visits; whether their state mandates fertility preservation coverage for medically induced infertility, which some do and many do not; whether their plan treats a wig as a prosthetic device, in which case it may be covered with a prescription using the term cranial prosthesis, or as cosmetic, in which case it is not; and what the plan's deductible and out-of-pocket maximum are.\n\nWhat has changed on the payment side. The Centers for Medicare and Medicaid Services Enhancing Oncology Model pays participating practices \"$110 per beneficiary per month (or $140 per beneficiary per month for dually eligible individuals)\" and requires them to deliver care activities including patient navigation, comprehensive care plans, screening for social needs and collection of electronic patient-reported outcomes. That is the first time several of the things on this front have been funded as a requirement rather than as an unreimbursed extra. It covers participating practices, selected cancers and Medicare beneficiaries, and runs to 30 June 2030.\n\nWhy this bears on measurement. Financial toxicity is itself measured, by the COST instrument, and the PRO-TECT weekly survey included a question on financial burden alongside symptoms. Treating cost as a side effect to be screened for is the approach the existing financial navigation record describes, and the evidence there is that navigation recovers more than it costs.\n\nWhat we did not verify in this round. Current state-by-state fertility preservation mandates, typical out-of-pocket costs for oocyte cryopreservation, and whether commercial plans commonly cover scalp cooling devices. These change frequently and were not sourced here; no figures are given in their place.","status":"established","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Health_insurance_in_the_United_States","links":[{"label":"Ngan et al., Financial toxicity amongst cancer patients and survivors: a comparative study of the United Kingdom and United States (Support Care Cancer 2025)","url":"https://doi.org/10.1007/s00520-025-09568-6"},{"label":"Centers for Medicare and Medicaid Services: Enhancing Oncology Model","url":"https://www.cms.gov/priorities/innovation/innovation-models/enhancing-oncology-model"}],"tags":["rejuvenation","survivorship","measurement","access","cost","us"],"related":["rejuv-access-what-it-costs-uk","rejuv-access-fertility-preservation"],"cancers":["breast-hr-positive","colorectal","multiple-myeloma","nsclc"],"sections":["rejuvenation","supportive-care"],"technologies":["financial-navigation","rejuv-life-money-after-treatment","rejuv-access-survivorship-care-us","rejuv-measure-epro-implementation","fertility-preservation","wigs-cranial-prosthesis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["financial-toxicity","quality-of-life"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-survivorship","b-incentive-misalignment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Where recovery services are paid for per encounter by a third party with discretion over coverage, the determinant of who receives them is the plan rather than the need. Bundling them into a per-patient monthly payment, as the Enhancing Oncology Model does, removes that discretion for the practices inside the model and for nobody else.","strengths":["A payment model now funds navigation, care plans, social needs screening and symptom collection as requirements","Financial toxicity is measured with a validated instrument and can be screened for","Financial navigation programmes have been shown to recover more than they cost"],"limitations":["More than half of survivors in the comparative survey reported financial toxicity","Coverage of rehabilitation, fertility preservation and wigs varies by plan and by state","The payment model covers selected practices and cancers and ends in 2030","Women reported higher risk of financial toxicity than men in the United States sample"]},"route":"/technologies/rejuv-access-what-it-costs-us/","neighbours":{"technology":[{"id":"rejuv-access-survivorship-care-us","kind":"technology","name":"After treatment in the United States: the survivorship care plan, and what the trial found","route":"/technologies/rejuv-access-survivorship-care-us/"},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/"},{"id":"rejuv-life-money-after-treatment","kind":"technology","name":"Money after treatment: what the cost of cancer does once the treatment has finished","route":"/technologies/rejuv-life-money-after-treatment/"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/"},{"id":"rejuv-measure-epro-implementation","kind":"technology","name":"What has actually been implemented since those trials, and what has not","route":"/technologies/rejuv-measure-epro-implementation/"},{"id":"rejuv-access-what-it-costs-elsewhere","kind":"technology","name":"What recovery costs in the rest of the world","route":"/technologies/rejuv-access-what-it-costs-elsewhere/"},{"id":"rejuv-access-what-it-costs-uk","kind":"technology","name":"What recovery costs in the UK, and what it does not","route":"/technologies/rejuv-access-what-it-costs-uk/"},{"id":"rejuv-access-fertility-preservation","kind":"technology","name":"Who gets told about fertility before treatment, and who does not","route":"/technologies/rejuv-access-fertility-preservation/"},{"id":"wigs-cranial-prosthesis","kind":"technology","name":"Wigs, cranial prostheses and head coverings","route":"/technologies/wigs-cranial-prosthesis/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"term":[{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"}]}}